Bladder Cancer

Of 2463 patients with urothelial cancer who underwent comprehensive genomic profiling, 39% harbored ≥1 tier 1-2 genomic alterations.

“The grasper disposable scope may fill the gap as an alternative to the conventional reusable cystoscope,” researchers concluded.

Tele-cystoscopy was found equivalent to traditional cystoscopy with respect to identification of abnormalities and action decisions.

Differences following surgery were related to the control of cancer and adjustments with urinary diversion.

"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes.

Investigators warn of the dangers of overprescribing antibiotics in cancer care.

The new dose would reduce a patient’s required medical visits by 50%.

Increased usage of bladder diagrams was observed following implementation of the program.

Including the genomic test in the protocol for patient surveillance reduced the average number of annual cystoscopies by approximately 39%.

The cost-savings are particularly noteworthy given prior evidence of blue light imaging enhancing the efficacy of diagnostic cystoscopy.

A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.

Intravesical Oncofid P-B, a conjugate of paclitaxel and hyaluronic acid, is active in patients with carcinoma in situ of the bladder that is not responsive to bacillus Calmette-Guérin.

Given the efficacy and safety demonstrated, there may be a role going forward for the pembrolizumab/nab-paclitaxel combination in earlier disease stages.

Intravesical instillations prevent recurrence of non–muscle-invasive bladder cancer.

The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.

72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.

Cabozantinib's single-agent activity opens the potential for combination approaches with immunotherapy in patients with heavily pretreated urothelial carcinoma.

BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

The FDA has approved the PD-L1 inhibitor avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.

Median overall survival is the same for both malignancies, study results show.

The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma.

Anti–PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant.

Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.